The P-III trial results published in NEJM evaluating VV116 vs nirmatrelvir–ritonavir (PAXLOVID) in 822 COVID-19 adult patients
As of data cut off Aug 2022, VV116 & PAXLOVID achieved noninferiority in the time to sustained clinical recovery in the FAS population, VV116 group had a shorter time to sustained clinical recovery (4 vs 5 days) with fewer safety concerns
Similar results were seen in both groups i.e., time to sustained resolution of all target symptoms & time to a first negative SARS-CoV-2 test with a median time of 7 days., clinical recovery was larger in VV116 (Days 5, 7, 10, 14 & 28), the incidence of AEs (67.4% vs 77.3%), grade 3 or 4 AE (2.6% vs 5.7%), no participants in either group had died or had had progression to sev. COVID-19 by Day 28
Ref: Globenewswire | Image: Junshi Biosciences
Related News:- Junshi Biosciences Reports Results of VV116 (JT001) in the P-III Registrational Trial for Early Treatment of COVID-19 in High Risk Patients
